MedPath

External Oblique Intercostal Plane Block for Liver Transplantation Recipient

Not Applicable
Not yet recruiting
Conditions
Liver Transplantation
Recipients of Liver Transplant
Postoperative Pain
Registration Number
NCT07233083
Lead Sponsor
Istinye University
Brief Summary

Postoperative pain management is one of the key factors in improving rehabilitation and accelerating recovery. The external oblique intercostal plane block can be used to provide abdominal wall analgesia for effective pain control in abdominal surgery.

The aim of this study is to investigate the postoperative analgesic efficacy of the external oblique intercostal plane block in liver transplant recipients.

The investigators will compare a group receiving the external oblique intercostal plane block with a control group to determine whether this block provides effective postoperative analgesia in liver transplant recipients.

Detailed Description

Patients scheduled for liver transplantation will be separated into 2 groups: External Oblique Intercostal Plane Block Group and Control Group.

Patients in the External Oblique Intercostal Plane Block Group will be performed bilateral External Oblique Intercostal Plane Block at the end of the surgery and after skin closure and will receive patient controlled analgesia with morphine for postoperative analgesia.

Patients in the Control Group will not receive any block procedure and will receive patient controlled analgesia with morphine for postoperative analgesia.

Morphine consumption for first postoperative 48 hours, visual analog scale scores, time to need for first rescue analgesia, amount of rescue analgesic drug, incidence of postoperative nausea and vomiting, and Quality of Recovery-15 scores will be recorded.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Adult patients aged 18 to 75 years

Scheduled for elective orthotopic liver transplantation (living or deceased donor)

J-shaped or Mercedes incision planned

ASA physical status III-IV

Normal or acceptable coagulation profile at the time of block application (INR ≤ 1.5, platelet count ≥ 50,000/mm³, fibrinogen ≥ 150 mg/dL)

Able to provide written informed consent

Exclusion Criteria
  • Coagulopathy at the time of block application (INR > 1.5, platelet count < 50,000/mm³, or fibrinogen < 150 mg/dL)

Known allergy or hypersensitivity to local anesthetics (amide group)

Local infection or skin lesion at the block injection site

Severe hemodynamic instability requiring high-dose vasopressor support

Chronic opioid use (≥30 mg oral morphine equivalents per day for ≥30 days before surgery)

Severe hepatic encephalopathy or cognitive impairment preventing use of PCA or pain scoring

Emergency or re-transplantation surgery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The amount of morphine required by the patient and given by the device will be recorded for the first 24 hoursPostoperative 24 hours
Secondary Outcome Measures
NameTimeMethod
Postoperative visual analog scale scoresPostoperative 24 hours

Postoperative pain will be assessed using a visual analog scale (VAS) (from 0 = no pain to 10 = maximum possible pain) for the first 24 hours.

Incidence of postoperative nausea and vomitingpostoperative 24 hours

Number of patients developing postoperative nausea and vomiting will be recorded for the first 24 hours

Rescue analgesic drug consumptionpostoperative 24 hours

The amount of rescue analgesic in mg required by the patient will be recorded for the first 24 hours

Trial Locations

Locations (1)

istinye University

Istanbul, Turkey (Türkiye)

istinye University
Istanbul, Turkey (Türkiye)
Taylan Sahin
Contact
905452303111
taylansah@hotmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.